India, June 5 -- This week, the biotech sector saw a wave of regulatory approvals in the U.S., alongside study halts, strategic collaborations, acquisitions, deal closures, and encouraging data readouts. Positive clinical study data readouts spanned multiple therapeutic areas, including Breast Cancer, Tumour-related Hyperinsulinism, RAS-mutated metastatic colorectal cancer, Systemic Lupus Erythematosus, IgA nephropathy, Myositis and Sjogren's disease. Let's dive into the details.
FDA Approvals and RejectionsFDA Clears Philips' Elevate Plus for Ultrasound Imaging
Koninklijke Philips N.V. (PHG) announced FDA 510(k) clearance and CE marking for Elevate Plus, an AI-powered upgrade to EPIQ Elite and Affiniti ultrasound platforms. The system im...